SOX2在头颈部鳞状细胞癌中的研究进展

摘要/Abstract

摘要： SOX2基因在胚胎干细胞的多能性及机体发育过程中起到重要作用，也是常见的肿瘤干细胞标志物之一，近年来研究证实，肿瘤干细胞与癌症的发生发展与转移扩散密切相关。本文就SOX2基因在头颈部鳞状细胞癌中早期诊断、增殖转移、预后及治疗等方面的机制和作用作一综述。

关键词: SOX2, 头颈部鳞状细胞癌, 肿瘤干细胞

Abstract: SOX2 gene plays an important role in the pluripotency and growth of embryonic stem cells, and is also one of the common tumor stem cell markers. Recent studies have confirmed that tumor stem cells are closely related to the occurrence, development and metastasis of cancer. This article reviews the mechanism and role of SOX2 gene in early diagnosis, proliferation, metastasis, prognosis and treatment of head and neck squamous cell carcinoma.

Key words: SOX2, head and neck squamous cell carcinoma, cancer stem cell

中图分类号:

R739.8

王雨萌魏欣王婧鲁晨费凡韩冰. SOX2在头颈部鳞状细胞癌中的研究进展[J]. 口腔医学, 2021, 41(9): 843-846.

参考文献 36

[1]	Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019 [J]. Ca-Cancer J Clin, 2019, 69(1): 7-34.
[2]	Gupta B, Johnson N W, Kumar N. Global Epidemiology of Head and Neck Cancers: A Continuing Challenge [J]. Oncology, 2016, 91(1): 13-23.
[3]	Stevanovic M, Zuffardi O, Collignon J, et al. The cDNA sequence and chromosomal location of the human SOX2 gene[J]. Mammalian Genome, 1994, 5(10): 640-642.
[4]	She Z Y, Yang W X. SOX family transcription factors involved in diverse cellular events during development[J]. European journal of cell biology, 2015, 94(12): 547-563.
[5]	Koyama-Nasu R, Haruta R, Nasu-Nishimura Y, et al. The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells[J]. Oncogene, 2014, 33(17): 2236-2244.
[6]	Boumahdi S, Driessens G, Lapouge G, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma[J]. Nature, 2014, 511(7508): 246-250.
[7]	Lengerke C, Fehm T, Kurth R, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma[J]. BMC cancer, 2011, 11(1): 42.
[8]	Voka? N K, ?izmarevi? B, Zagorac A, et al. An evaluation of SOX2 and hTERC gene amplifications as screening markers in oral and oropharyngeal squamous cell carcinomas[J]. Molecular cytogenetics, 2014, 7(1): 5.
[9]	Luiz S T, Modolo F, Mozzer I, et al. Immunoexpression of SOX-2 in oral leukoplakia [J]. Oral Dis, 2018, 24(8): 1449-57.
[10]	de Vicente J C, Donate-Pérez del Molino P, Rodrigo J P, et al. SOX2 Expression Is an Independent Predictor of Oral Cancer Progression[J]. Journal of clinical medicine, 2019, 8(10): 1744.
[11]	Naini F B, Shakib P A, Abdollahi A, et al. Relative Expression of OCT4, SOX2 and NANOG in Oral Squamous Cell Carcinoma Versus Adjacent Non-Tumor Tissue[J]. Asian Pacific journal of cancer prevention: APJCP, 2019, 20(6): 1649.
[12]	Ghazi N, Aali N, Shahrokhi V R, et al. Relative Expression of SOX2 and OCT4 in Oral Squamous Cell Carcinoma and Oral Epithelial Dysplasia[J]. Reports of Biochemistry & Molecular Biology, 2020, 9(2): 171.
[13]	Vijayakumar G, Narwal A, Kamboj M, et al. Association of SOX2, OCT4 and WNT5A Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma: An Immunohistochemical Study[J]. Head and Neck Pathology, 2020: 1-9.
[14]	Chien C S, Wang M L, Chu P Y, et al. Lin28B/Let-7 regulates expression of Oct4 and Sox2 and reprograms oral squamous cell carcinoma cells to a stem-like state[J]. Cancer research, 2015, 75(12): 2553-2565.
[15]	Bourguignon L Y W, Wong G, Earle C, et al. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma[J]. Journal of Biological Chemistry, 2012, 287(39): 32800-32824.
[16]	Lee S H, Oh S Y, Do S I, et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma[J]. British journal of cancer, 2014, 111(11): 2122-2130.
[17]	Tsuji T, Ibaragi S, Hu G. Epithelial-mesenchymal transition and cell cooperativity in metastasis[J]. Cancer research, 2009, 69(18): 7135-7139.
[18]	Liu X, Qiao B, Zhao T, et al. Sox2 promotes tumor aggressiveness and epithelial?mesenchymal transition in tongue squamous cell carcinoma[J]. International journal of molecular medicine, 2018, 42(3): 1418-1426.
[19]	Keysar S B, Le P N, Miller B, et al. Regulation of head and neck squamous cancer stem cells by PI3K and SOX2[J]. Journal Of The National Cancer Institute, 2017, 109(1): djw189.
[20]	Deng P, Wang J, Zhang X, et al. AFF4 promotes tumorigenesis and tumor-initiation capacity of head and neck squamous cell carcinoma cells by regulating SOX2[J]. Carcinogenesis, 2018, 39(7): 937-947.
[21]	Ren L, Deng B, Saloura V, et al. MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells[J]. Oncology Reports, 2019, 41(4): 2540-2548.
[22]	Li J, Li Z, Wu Y, et al. The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma[J]. Cell death & disease, 2019, 10(8): 1-15.
[23]	Lv X X, Zheng X Y, Yu J J, et al. EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2[J]. Cancer Medicine, 2020, 9(3): 1131-1140.
[24]	Bayo P, Jou A, Stenzinger A, et al. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma[J]. Molecular oncology, 2015, 9(8): 1704-1719.
[25]	Chung J H, Jung H R, Jung A R, et al. SOX2 activation predicts prognosis in patients with head and neck squamous cell carcinoma[J]. Scientific reports, 2018, 8(1): 1-11.
[26]	Yoshihama R, Yamaguchi K, Imajyo I, et al. Expression levels of SOX2, KLF4 and brachyury transcription factors are associated with metastasis and poor prognosis in oral squamous cell carcinoma[J]. Oncology letters, 2016, 11(2): 1435-1446.
[27]	Wang X, Liang Y, Chen Q, et al. Prognostic significance of SOX2 expression in nasopharyngeal carcinoma[J]. Cancer investigation, 2012, 30(1): 79-85.
[28]	Pedregal-Mallo D, Hermida-Prado F, Granda-Díaz R, et al. Prognostic Significance of the Pluripotency Factors NANOG, SOX2, and OCT4 in Head and Neck Squamous Cell Carcinomas[J]. Cancers, 2020, 12(7): 1794.
[29]	Baumeister P, Hollmann A, Kitz J, et al. High expression of EpCAM and Sox2 is a positive prognosticator of clinical outcome for head and neck carcinoma[J]. Scientific reports, 2018, 8(1): 1-15.
[30]	Bochen F, Adisurya H, Wemmert S, et al. Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas[J]. Oncotarget, 2017, 8(3): 4922.
[31]	Pradhan S, Guddattu V, Solomon M C. Association of the co-expression of SOX2 and Podoplanin in the progression of oral squamous cell carcinomas-an immunohistochemical study[J]. Journal of Applied Oral Science, 2019, 27.
[32]	Attramadal C G, Halstensen T S, Dhakal H P, et al. High nuclear SOX 2 expression is associated with radiotherapy response in small (T1/T2) oral squamous cell carcinoma[J]. Journal of Oral Pathology & Medicine, 2015, 44(7): 515-522.
[33]	Schr?ck A, Bode M, G?ke F J M, et al. Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma[J]. Carcinogenesis, 2014, 35(7): 1636-1642.
[34]	Liang X, Deng M, Zhang C, et al. Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2[J]. Cancer letters, 2019, 454: 108-119.
[35]	Tan Y S, Sansanaphongpricha K, Xie Y, et al. Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine[J]. Clinical Cancer Research, 2018, 24(17): 4242-4255.
[36]	Hsieh M H, Choe J H, Gadhvi J, et al. p63 and SOX2 dictate glucose reliance and metabolic vulnerabilities in squamous cell carcinomas[J]. Cell reports, 2019, 28(7): 1860-1878. e9.